tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Orchitis D009920 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Opportunistic Infections D009894 8 associated lipids
Oliguria D009846 2 associated lipids
Obesity D009765 29 associated lipids
Nocardia Infections D009617 6 associated lipids
Neutropenia D009503 15 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Neurodermatitis D009450 1 associated lipids
Neuritis D009443 4 associated lipids
Nervous System Diseases D009422 37 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis D009393 19 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Nail Diseases D009260 2 associated lipids
Myxedema D009230 2 associated lipids
Myelitis D009187 1 associated lipids
Mycoses D009181 18 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mutism D009155 1 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Moyamoya Disease D009072 1 associated lipids
Mouth Diseases D009059 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mite Infestations D008924 1 associated lipids
Metaplasia D008679 7 associated lipids
Meningoencephalitis D008590 4 associated lipids
Meningococcal Infections D008589 3 associated lipids
Memory Disorders D008569 33 associated lipids
Melanoma D008545 69 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Mediastinitis D008480 2 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mastocytosis D008415 5 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Malacoplakia D008287 1 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoma D008223 18 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphocele D008210 1 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Abscess D008169 1 associated lipids
Long QT Syndrome D008133 10 associated lipids
Liver Diseases D008107 31 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Abscess D008100 6 associated lipids
Listeriosis D008088 12 associated lipids
Lichen Planus D008010 3 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Leukoplakia D007971 1 associated lipids
Leukocytosis D007964 9 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia D007938 74 associated lipids
Lentigo D007911 1 associated lipids
Legionellosis D007876 3 associated lipids
Leg Injuries D007869 2 associated lipids
Labyrinthitis D007762 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Diseases D007674 29 associated lipids
Keloid D007627 12 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Ischemia D007511 18 associated lipids
Intussusception D007443 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intertrigo D007402 1 associated lipids
Insulin Resistance D007333 99 associated lipids
Influenza, Human D007251 11 associated lipids
Inflammation D007249 119 associated lipids
Infection D007239 6 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Impetigo D007169 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Dinçkan A et al. Evaluation of the first 100 liver transplantations. 2008 Turk J Gastroenterol pmid:18386237
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Suzuki H et al. Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. 1997 Transplantation pmid:9293881
Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. 2006 Transplantation pmid:16861943
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
McGhee B et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. 1997 Transplantation pmid:9326429
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Kaplan B et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. 1999 Transplantation pmid:10075604
Erden E et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. 1994 Transplantation pmid:7519801
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Ciancio G et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. 2004 Transplantation pmid:15316372
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Nankivell BJ et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. 2016 Transplantation pmid:27306529
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241